JLJiao Liu

Jiao Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiao Liu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Liona C. Poon

    Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR; Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China

    3 shared publications
  • Hao Ying

    Department of Obstetrics, Shanghai Key Laboratory of Maternal Fetal Medicine Shanghai Institute of Maternal‐Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University Shanghai China

    2 shared publications
  • Huixia Yang

    Department of Obstetrics and Gynaecology and Reproductive Medicine Peking University First Hospital Beijing China

    2 shared publications
  • Xiaohong Lu

    Department of Obstetrics and Gynaecology Prince of Wales Hospital, The Chinese University of Hong Kong Hong Kong SAR China

    2 shared publications
  • Xiaotian Li

    Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, China

    2 shared publications
  • Alex Pui-Wai Lee

    The Chinese University of Hong Kong

    1 shared publication

Latest Publications

  • Open Access

    Assessing quality standards of biomarker measurement in first‐trimester combined screening for preeclampsia in the Chinese population: A multicenter study

    by Jiao Liu, Xiaotian Li, Huixia Yang, Qiongjie Zhou, Hao Ying, Rong Zhou, Yanping Zhang, Wang Xueyin, Han Xie, Xinzhi Tu, et al.

    Introduction: The first‐trimester combined screening test for preterm preeclampsia (preterm‐PE) has been implemented in Mainland China. This study aims, first, to evaluate the applicability of multiple of the median (MoM) models based on biomarkers developed and utilized in a European population for prospective preterm‐PE screening in Mainland China; second, to assess the criteria for biomarker adjustment; and third, to establish criteria for continuous quality assurance in the screening process. Material and Methods: In this prospective multicenter cross‐sectional study, 22 066 singleton pregnancies undergoing preterm‐PE screening at 11 + 0 –13 + 6 weeks were recruited from six tertiary hospitals in Mainland China. Mean arterial pressure (MAP) and placental growth factor (PlGF) were measured and converted to their equivalent MoM values using Fetal Medicine Foundation MoMing models incorporated in commercial software. PlGF levels were also determined using immunoassays developed in China. MoM and log 10 MoM distributions in the initial screened subjects were assessed for (1) central tendency and dispersion and (2) whether biomarker MoM distributions needed to be recentered. Biomarker central tendency and temporal stability both before and after recentering were assessed using Cumulative Sum plots. Distribution central tendency was considered good if its median MoM was between 0.95 and 1.05 and acceptable if between 1.05 and 1.10. Results: After excluding the initial 400 pregnancies from each center, all PlGF, but not all MAP MoM distributions, required recentering. Post‐recentering, the overall distribution median (95% confidence interval) MoM values for MAP and PlGF were 1.003 (1.001, 1.004) and 1.004 (0.996, 1.013), respectively. Conclusions: Chinese centers performing combined PE screening should assess biomarker MoM distributions in their initial cases to ensure that they conform to the expected central tendencies assumed in the risk estimation models.

  • Effect of Parity and Previous Preeclampsia on Maternal Hemodynamics

    by Yunyu Chen, Jing Lin, Xueqin Wang, Iok Seng Wong, Jiao Liu, Fangzi Liu, So Ling Lau, Janice S.Y. Wong, Hillary H.Y. Leung, Alex P.W. Lee, et al.

    BACKGROUND: The effect of parity and previous preeclampsia on the longitudinal maternal hemodynamics during pregnancy has not been studied. METHODS: This was a prospective longitudinal study of maternal hemodynamic profile, assessed by transthoracic echocardiography, for women at 12 +0 to 15 +6 , 20 +0 to 24 +6 , and 30 +0 to 37 +6 weeks of gestation. The study populations were divided into 3 groups: nulliparous women and parous women with and without previous preeclampsia. A linear mixed-effects analysis was performed to compare the longitudinal changes in hemodynamics across gestation among the study groups, controlling for maternal characteristics and medical history in the index pregnancy. RESULTS: Our study involved 760 nulliparous women, 318 parous women without previous preeclampsia, and 59 parous women with previous preeclampsia. The parous with previous preeclampsia group had the highest median mean arterial pressure and systemic vascular resistance compared with the other 2 groups throughout gestation (all P +6 and 30 +0 to 37 +6 weeks. Parous women without previous preeclampsia demonstrated a higher estimated marginal mean of cardiac output and a lower estimated marginal mean of systemic vascular resistance compared with nulliparous women throughout gestation (all P <0.05). CONCLUSIONS: The study has revealed that parous women without previous preeclampsia show optimal cardiovascular responses. In contrast, those with a history of preeclampsia exhibit suboptimal cardiovascular adaptation, and the cardiovascular changes observed from the second trimester in the index pregnancy are attributed to maternal characteristics and the development of preeclampsia.

  • Open Access

    Aspirin versus metformin in pregnancies at high risk of preterm pre-eclampsia in China (AVERT): protocol for a multicentre, double-blind, 3-arm randomised controlled trial

    by Jiao Liu, Lixia Shen, Long Nguyen-Hoang, Qiongjie Zhou, Chi Chiu Wang, Xiaohong Lu, Daljit Sahota, Ka Chun Chong, Hao Ying, Weirong Gu, et al.

    Introduction Pre-eclampsia (PE) affects about 5% of Chinese pregnant women and is a major cause of maternal and perinatal morbidity and mortality. The first trimester screening model developed by the Fetal Medicine Foundation, which uses the Bayes theorem to combine maternal characteristics and medical history together with measurements of biomarkers, has been proven to be effective and has superior screening performance to that of the traditional risk factor-based approach for the prediction of PE. Prophylactic use of low-dose aspirin in women at risk for PE has resulted in a lower incidence of preterm-PE. However, there is no consensus on the preferred aspirin dosage for the prevention of preterm-PE. Evidence has also suggested that metformin has the potential benefit in preventing PE in pregnant women who are at high risk of the disorder. Method and analysis We present a protocol (V.2.0, date 17 March 2022) for the AVERT trial, which is a multicentre, double-blinded, 3-arm randomised controlled trial (RCT) that uses an effective PE screening programme to explore the optimal dosage of aspirin and the role of metformin for the prevention of PE among high-risk pregnant women in China. We intend to recruit 66 000 singleton pregnancies without treatment of low-dose aspirin and metformin at 11–13 weeks’ gestation and all eligible women attending for their first trimester routine scan will be invited to undergo screening for preterm-PE by the combination of maternal factors, mean arterial pressure and placental growth factor. Women found to be at high risk of developing preterm-PE will be invited to take part in the RCT. This study will compare the incidence of preterm-PE with delivery at Ethics and dissemination Ethical approval for the study was obtained from the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee (CREC Ref. No. 2021.406) in Hong Kong and the Ethics Committee of each participating hospital in Mainland China. The study is registered at ClinicalTrials.gov. The results of the AVERT trial will be disseminated at international academic conferences and published in high-impact factor journals. Trial registration number NCT05580523.


  • Open Access

    Inpatient use of metformin and acarbose is associated with reduced mortality of COVID‐19 patients with type 2 diabetes mellitus

    by Jinghong Li, Qi Wei, Karen C. McCowen, Wei Xiong, Jiao Liu, Wenlijun Jiang, Robert L. Thomas, Mark Hepokoski, Ming He, John Y. J. Shyy, et al.

    Aims: Type 2 diabetes mellitus (T2DM) is a strong risk factor for complications of coronavirus disease 2019 (COVID‐19). The effect of T2DM medications on COVID‐19 outcomes remains unclear. In a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID‐19 in Wuhan, we have previously found that metformin use prior to hospitalization is associated with reduced mortality. The current study aims to investigate the effects of inpatient use of T2DM medications, including metformin, acarbose, insulin and sulfonylureas, on the mortality of COVID‐19 patients with T2DM during hospitalization.Methods: We continue to carry out a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID‐19 and treated with different combinations of diabetes medications.Results: We found that patients using metformin (p = .02) and acarbose (p = .04), alone or both together (p = .03), after admission were significantly more likely to survive than those who did not use either metformin or acarbose. 37 patients continued to take metformin after admission and 35 (94.6%) survived. Among the 57 patients who used acarbose after admission, 52 survived (91.2%). A total of 20 patients used both metformin and acarbose, while 57 used neither. Of the 20 dual‐use patients, 19 (95.0%) survived.Conclusion: Our analyses suggest that inpatient use of metformin and acarbose together or alone during hospitalization should be studied in randomized trials.